

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of claims:

1. (currently amended) A pharmaceutical composition of matter in the form of a solution concentrate comprising a cyclosporin dissolved in dimethyl sulfoxide (DMSO) wherein the concentration of cyclosporin is ~~at least~~ from 0.1% to 90% by weight of the total composition.

2. (previously presented) A composition as in claim 1 wherein the cyclosporin is cyclosporin A.

3. (currently amended) A method for administering cyclosporin into cerebrospinal fluid spaces, which comprises ~~comprises~~:

providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection into the cerebrospinal fluid spaces to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

4. (currently amended) A method for administering cyclosporin by injection including intra-ocular, intravestibular, into or adjacent to the brain, or spinal cord, to a patient, the improvement which comprises ~~comprises~~: providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection intra-ocular, intravestibular, into or adjacent to the brain, or spinal cord to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

5. (currently amended) A method for administering cyclosporin by injection including intravenous, intra-arterial or intraparenchymal, into a patient, the improvement which comprises ~~comprises~~: providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection into intravenous, intra-arterial or intraparenchymal spaces to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

6. (currently amended) A method for administering cyclosporin orally, inhalationally (See PCT page 5 Medicament and Administration) rectally, vaginally, urethrally, bladder

cisternally, (same reference), nasally, intra and peri-ocularly
(PCT page 5 medicament and Administration:""intra and peri-
ocular instillation including application by injection around
the eye, within the eyeball, its structures and layers") or
dermally to a patient, the improvement which comprises
~~comprises~~: providing the cyclosporin dissolved in DMSO in a
pharmaceutically acceptable carrier, and administering said
cyclosporin and DMSO solution orally,inhalationally, rectally,
vaginally, urethrally, bladder cisternally, nasally, -intra and
peri-ocularly or dermally to said patient wherein said
cyclosporin is present in an amount of from 0.1 to 90% by weight
of the total composition.

7. (previously presented) The method of claim 3 wherein the
cyclosporin is cyclosporin A, or functional derivatives,
metabolites, variants or salts thereof.

8. (currently amended) An article of manufacture comprising
packaging material and pharmaceutical agent is therapeutically
effective for reducing or preventing neuronal damage and for
causing immunosuppression when administered in a therapeutically
effective quantity, and wherein the packaging material comprises
a label which indicates that the pharmaceutical agent can be
used for reducing or preventing neuronal damage and for causing

immunosuppression, and wherein said pharmaceutical agent comprises DMSO and a cyclosporin or functional derivatives wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition, metabolites, variants or salts thereof, or a combination of the before said, either alone or in admixture with diluents or additives.

9. (previously presented) The article of manufacture according to claim 8, wherein the cyclosporin is selected from the group consisting of cyclosporin A and a compound of the class of cyclosporins.

10. (currently amended) The method according to claim 3 wherein the administering of cyclosporin into cerebrospinal fluid spaces is intraventricular and intrathecal.

11. (New) An improved method for treating Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV neuropathy, Guillain-Barré syndrome, neural transplantation, neural xenotransplantation, stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity of vestibulocochlear structures, and retinal detachment which comprises administering cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and

administering said cyclosporin and DMSO solution to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.

12. (New) An improved method for inducing systemic immunosuppression in patients with transplantation and autoimmune disease which comprises administering cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution to said patient wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total composition.